Final Rule- CLIA Fees, histocompatibility, personnel, and alternative sanctions for Certificate of Waiver laboratories (CMS-3326-F)

CMS memo.
April 16, 2024
2 min read

The Centers for Medicare & Medicaid Services published a final rule on CLIA Fees, histocompatibility, personnel, and alternative sanctions for Certificate of Waiver laboratories.

Memorandum summary:

• Publication of Final Rule: CMS-3326-F was published on December 28, 2023. This final rule updates the Clinical Laboratory Improvement Amendments of 1988 (CLIA) fees and clarifies the CLIA fee regulations. Specifically, the final rule will: 1) implement a process for sustainable funding for the CLIA program through a biennial two-part increase of CLIA fees; 2) amend histocompatibility and personnel regulations under CLIA to address obsolete regulations and update the regulations to incorporate technological changes; and 3) amend the provisions governing alternative sanctions (including civil money penalties, a directed plan of correction, a directed portion of a plan of correction, and onsite State monitoring) to allow for the imposition of such sanctions against non-compliant laboratories operating under Certificates of Waiver, rather than being limited only to imposing principal sanctions of revocation, suspension or limitation of a laboratory’s CLIA certificate.

• Effective Dates: These regulations are effective January 27, 2024, except for instruction 3, amending § 493.2; instructions 14 through 19, amending §§ 493.945, 493.1273, 493.1274, 493.1278, 493.1359, and 493.1405; instruction 20 removing § 493.1406; instructions 21 through 30, amending §§ 493.1407, 493.1411, 493.1417, 493.1423, 493.1443, 493.1445, 493.1449, 493.1451, 493.1455, and 493.1461; instruction 31 removing § 493.1462; and instructions 32 through 36, amending §§ 493.1463, 493.1469, 493.1483, 493.1483, 493.1489, and 493.1491, which are effective December 28, 2024.

CMS memo

About the Author

Sign up for Medical Laboratory Observer eNewsletters